$4.06
Cancer therapies developer Theseus Pharmaceuticals wrapped its initial public offering Thursday, selling 10 million shares at $16 each, the high end of its proposed range. The stock will debut on the Nasdaq later today under the ticker symbol THRX, but shares are available for limit orders at Robinhood and other platforms.
Our top picks for where to buy Theseus Pharmaceuticals stock
How to buy Theseus Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – THRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Theseus Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Theseus Pharmaceuticals stock price (NASDAQ: THRX)
Use our graph to track the performance of THRX stocks over time.Theseus Pharmaceuticals shares at a glance
Latest market close | $0.00 |
---|---|
52-week range | $2.05 - $4.20 |
50-day moving average | $4.02 |
200-day moving average | $4.47 |
Wall St. target price | $5.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.34 |
Is it a good time to buy Theseus Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Theseus Pharmaceuticals price performance over time
Historical closes compared with the close of $0 from 2024-02-27
1 week (2024-08-27) | nan% |
---|---|
1 month (2024-08-03) | nan% |
3 months (2024-06-03) | nan% |
6 months (2024-03-03) | nan% |
1 year (2023-09-07) | -100.00% |
---|---|
2 years (2022-09-07) | -100.00% |
3 years (2021-09-03) | N/A |
5 years (2019-09-03) | N/A |
Theseus Pharmaceuticals financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -17.89% |
Return on equity TTM | -25.55% |
Profit margin | 0% |
Book value | $5.17 |
Market Capitalization | $181.3 million |
TTM: trailing 12 months
Theseus Pharmaceuticals share dividends
We're not expecting Theseus Pharmaceuticals to pay a dividend over the next 12 months.
Theseus Pharmaceuticals share price volatility
Over the last 12 months, Theseus Pharmaceuticals's shares have ranged in value from as little as $2.05 up to $4.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theseus Pharmaceuticals's is 3.984. This would suggest that Theseus Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Theseus Pharmaceuticals's beta into context you can compare it against those of similar companies.
- Praxis Precision Medicines Inc (PRAX.US): 2.741
- Aslan Pharmaceuticals Ltd ADR (ASLN.US): 1.399
- Cardiff Oncology (CRDF.US): 1.936
Theseus Pharmaceuticals overview
Theseus Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc.
Frequently asked questions
What percentage of Theseus Pharmaceuticals is owned by insiders or institutions?Currently 2.557% of Theseus Pharmaceuticals shares are held by insiders and 84.083% by institutions. How many people work for Theseus Pharmaceuticals?
Latest data suggests 38 work at Theseus Pharmaceuticals. When does the fiscal year end for Theseus Pharmaceuticals?
Theseus Pharmaceuticals's fiscal year ends in December. Where is Theseus Pharmaceuticals based?
Theseus Pharmaceuticals's address is: 314 Main Street, Cambridge, MA, United States, 02142 What is Theseus Pharmaceuticals's ISIN number?
Theseus Pharmaceuticals's international securities identification number is: US88369M1018
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question